Los Angeles Capital Management & Equity Research Inc. Invests $132,000 in BioCryst Pharmaceuticals, Inc. (BCRX) Stock

Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 25,170 shares of the biotechnology company’s stock, valued at approximately $132,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Legal & General Group Plc raised its stake in shares of BioCryst Pharmaceuticals by 4.9% in the second quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 860 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of BioCryst Pharmaceuticals by 4.7% in the second quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock worth $185,000 after acquiring an additional 1,500 shares during the last quarter. Pacad Investment Ltd. bought a new position in shares of BioCryst Pharmaceuticals in the second quarter worth about $196,000. Bank of America Corp DE raised its stake in shares of BioCryst Pharmaceuticals by 43.3% in the first quarter. Bank of America Corp DE now owns 25,029 shares of the biotechnology company’s stock worth $210,000 after acquiring an additional 7,568 shares during the last quarter. Finally, Voya Investment Management LLC raised its stake in shares of BioCryst Pharmaceuticals by 12.1% in the second quarter. Voya Investment Management LLC now owns 38,275 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 4,127 shares during the last quarter. 84.69% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have weighed in on BCRX shares. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $15.00 target price (up from $13.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 5th. Noble Financial reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 8th. ValuEngine raised shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, September 6th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $9.13.

Shares of BioCryst Pharmaceuticals, Inc. (BCRX) opened at $4.70 on Wednesday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $3.95 and a 1 year high of $9.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.53 and a current ratio of 2.53.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) EPS for the quarter, hitting the consensus estimate of ($0.18). BioCryst Pharmaceuticals had a negative net margin of 167.58% and a negative return on equity of 123.16%. The company had revenue of $8.76 million during the quarter, compared to analysts’ expectations of $5.05 million. During the same quarter in the previous year, the company earned ($0.16) EPS. BioCryst Pharmaceuticals’s revenue was up 12.9% on a year-over-year basis. equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

In other news, Director Fred E. Cohen sold 54,250 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $5.42, for a total transaction of $294,035.00. Following the completion of the sale, the director now owns 173,660 shares in the company, valued at approximately $941,237.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CMO William P. Sheridan sold 64,310 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $4.72, for a total transaction of $303,543.20. The disclosure for this sale can be found here. 5.60% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “Los Angeles Capital Management & Equity Research Inc. Invests $132,000 in BioCryst Pharmaceuticals, Inc. (BCRX) Stock” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2017/12/06/los-angeles-capital-management-equity-research-inc-invests-132000-in-biocryst-pharmaceuticals-inc-bcrx-stock.html.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply